Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Blood|February 22, 2003
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndromeJorge Cortes, Patricia Ault, Charles Koller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Jorge Cortes, et al.
Leukemia Research|July 16, 2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaApostolia Tsimberidou, Jorge Cortes, Deborah Thomas, et al.
Cancer|April 4, 2003
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemiaSherif Ibrahim, Iman Jilani, Susan O'Brien, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Leukemia Research|August 15, 2009
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemiaJean-Marie Bruey, Hagop Kantarjian, Zeev Estrov, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.
Pageof 16